Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MORF
- Price
- -
- Stock movement up
- +0.01 (0.01%)
- Company name
- Morphic Holding Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.86B
- Ent value
- 2.84B
- Price/Sales
- -
- Price/Book
- 4.63
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 14.91%
- 1 year return
- 10.66%
- 3 year return
- -2.16%
- 5 year return
- 20.56%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
MORF does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 4.63 |
| EV to Sales | -47.13 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.22M |
| EPS (TTM) | -3.59 |
| FCF per share (TTM) | -2.75 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -60.24M |
| Gross profit (TTM) | -61.36M |
| Operating income (TTM) | -213.02M |
| Net income (TTM) | -179.83M |
| EPS (TTM) | -3.59 |
| EPS (1y forward) | -3.67 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 101.86% |
| Operating margin (TTM) | 353.64% |
| Profit margin (TTM) | 298.54% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 50.77M |
| Net receivables | 0.00 |
| Total current assets | 639.50M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 5.64M |
| Total assets | 646.09M |
| Accounts payable | 7.05M |
| Short/Current long term debt | 3.32M |
| Total current liabilities | 26.50M |
| Total liabilities | 27.66M |
| Shareholder's equity | 618.43M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -136.30M |
| Capital expenditures (TTM) | 1.35M |
| Free cash flow (TTM) | -137.65M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -29.08% |
| Return on Assets | -27.83% |
| Return on Invested Capital | -28.98% |
| Cash Return on Invested Capital | -22.18% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| MORF | S&P500 | |
| Current price drop from All-time high | -32.83% | -1.87% |
| Highest price drop | -76.74% | -56.47% |
| Date of highest drop | 13 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -42.82% | -11.07% |
| Avg time to new high | 65 days | 12 days |
| Max time to new high | 873 days | 1805 days |
COMPANY DETAILS
Marketcap
2.86B
Marketcap category
Mid-cap
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Employees
128
Website
Investor relations
-
SEC filings
CEO
Praveen P. Tipirneni
Country
USA
City
Waltham
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner